Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Alexion Pharmaceuticals, Inc. ALXN
$182.50
На 18:00, 12 мая 2023
-20.88%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
187.45
-
week52low
99.91
-
Revenue
6069900000
-
P/E TTM
66
-
Beta
1.25952100
-
EPS
3.08100000
-
Last Dividend
0.00000000
-
Next Earnings Date
29 июл 2021 г. в 04:00
Описание компании
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
Grading company | New grade | Previous grade | Recommendation date |
---|---|---|---|
SVB Leerink | Market Perform | Outperform | 23 мар 2021 г. |
SVB Leerink | Outperform | Outperform | 05 февр 2021 г. |
Raymond James | Market Perform | Outperform | 08 янв 2021 г. |
Truist Securities | Hold | Buy | 16 дек 2020 г. |
Citigroup | Neutral | Buy | 15 дек 2020 г. |
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Insider Summary
Insider Summary
Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
---|---|---|---|---|
Bazarko Daniel | D | 0 | 60207 | 21 июл 2021 г. |
FRIEDMAN PAUL A | D | 0 | 12840 | 21 июл 2021 г. |
Dunsire Deborah | D | 0 | 14629 | 21 июл 2021 г. |
Mollen John T | D | 0 | 15336 | 21 июл 2021 г. |
HANTSON LUDWIG | D | 0 | 56762 | 21 июл 2021 г. |
HANTSON LUDWIG | D | 9098 | 580809 | 21 июл 2021 г. |
ORLOFF JOHN J | D | 0 | 146511 | 21 июл 2021 г. |
Brennan David R | D | 0 | 20873 | 21 июл 2021 г. |
SARIN ARADHANA | D | 0 | 120253 | 21 июл 2021 г. |
Carino Tanisha | D | 0 | 59226 | 21 июл 2021 г. |
Institutional Ownership
Institutional Ownership
Holder | Shares | Change | Date Reported |
---|---|---|---|
Vanguard Total Stock Market Index Fund | 5916050 | -51787 | 31 авг 2020 г. |
Vanguard 500 Index Fund | 4537000 | -17687 | 31 авг 2020 г. |
Invesco QQQ Trust | 2518920 | 38701 | 31 авг 2020 г. |
SPDR S&P 500 ETF | 2326170 | -11039 | 31 авг 2020 г. |
iShares NASDAQ Biotechnology ETF | 2267230 | -20637 | 31 авг 2020 г. |
US Bank Vanguard Institutional 500 Index Trust | 1897010 | -9110 | 31 авг 2020 г. |
iShares Core S&P 500 ETF | 1670800 | -9044 | 31 авг 2020 г. |
Fidelity 500 Index Fund | 1967010 | -2128 | 31 июл 2020 г. |
ClearBridge Large Cap Growth Fund | 2173700 | 147458 | 30 июн 2020 г. |
T. Rowe Price Health Sciences Fund | 1671850 | 106738 | 30 июн 2020 г. |
Свежие комментарии
Свежие комментарии